Form 8-K PROTEON THERAPEUTICS For: Mar 28
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Proteon Therapeutics (PRTO) PT Lowered to $1 at Baird
March 28, 2019 11:19 AM EDTBaird analyst Michael Ulz lowered the price target on Proteon Therapeutics (NASDAQ: PRTO) to $1.00 (from $3.00) while maintaining a Neutral rating.
Ulz commented, "This morning, Proteon announced disappointing top-line results from the Phase 3 PATENCY-2 study of vonapanitase, indicating the co-primary endpoints of fistula use for... More
